Concord Healthcare sees H1 revenue rising 29%-39% to RMB 260-280 million

• Concord Healthcare guided for H1 2026 revenue of RMB 260 million–RMB 280 million, up 29%–39% from RMB 200.9 million a year earlier.
• Gross profit expected at RMB 63 million–RMB 83 million, versus RMB 0.38 million in H1 2025, implying growth of 16,349%–21,571%.
• Outlook driven by higher proton therapy revenue at Guangzhou Concord Cancer Center; cumulative patients exceeded 1,000, daily treatments topped 100.
• Interim results expected by end-August 2026; figures based on unaudited management accounts and may be adjusted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Concord Healthcare Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12261603), on July 30, 2026, and is solely responsible for the information contained therein.